BioMarin CEO JJ Bienaimé is planning for a blockbuster future in the gene therapy biz: to the tune of $10B to $15B a year
The economics of gene therapy has captured just about everyone’s attention in the industry. This first wave is faced with stubborn questions about durability, the race to first-in-class status as well as the sticky issue of just how much money you can make from these supposedly once-and-done therapies that can cure patients of some terrible diseases.
BioMarin CEO Jean-Jacques Bienaimé felt the full force of that blowback from a range of analysts in yesterday’s Q4 call. And at one point in the conversation, he offered a snapshot of what the future could look like — and it’s a big one.
Basic subscription required
Unlock this story instantly and join 54,600+ biopharma pros reading Endpoints daily — and it's free.